MAB626-100

antibody from R&D Systems

Targeting: TNFSF11 CD254, ODF, OPGL, RANKL, TRANCE

Immunohistochemistry (Supportive data in Antibodypedia)

Blocking/Neutralizing (Supportive data in Antibodypedia)

Antibody Data

Product number

MAB626-100

Provider

R&D Systems

Product name

Human TRANCE/TNFSF11/RANK L Antibody

Antibody type

Monoclonal

Description

Protein A or G purified from ascites. Detects human TRANCE/TNFSF11/RANK L in direct ELISAs. No cross-reactivity with recombinant mouse TRANCE is observed.

Reactivity

Human

Host

Mouse

Conjugate

Unconjugated

Antigen sequence

O14788


Isotype

IgG

Antibody clone number

70525

Vial size

100 ug

Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.

References

Submitted references

Proteinase-activated receptor (PAR)-2 activation impacts bone resorptive properties of human osteoarthritic subchondral bone osteoblasts.

Amiable N, Tat SK, Lajeunesse D, Duval N, Pelletier JP, Martel-Pelletier J, Boileau C
Bone 2009 Jun;44(6):1143-50

---

A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies.

Lee N, Smolarz AJ, Olson S, David O, Reiser J, Kutner R, Daw NC, Prockop DJ, Horwitz EM, Gregory CA
British journal of cancer 2007 Dec 3;97(11):1552-9

---

Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis.

Makrygiannakis D, af Klint E, Catrina SB, Botusan IR, Klareskog E, Klareskog L, Ulfgren AK, Catrina AI
Arthritis and rheumatism 2006 May;54(5):1463-72

---

Inflammatory cell infiltrate and RANKL/OPG expression in rheumatoid synovium: comparison with other inflammatory arthropathies and correlation with outcome.

Fonseca JE, Cortez-Dias N, Francisco A, Sobral M, Canhão H, Resende C, Castelão W, Macieira C, Sequeira G, Saraiva F, da Silva JA, Carmo-Fonseca M, Viana Queiroz M
Clinical and experimental rheumatology 2005 Mar-Apr;23(2):185-92

---

Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.

Mandelin J, Li TF, Hukkanen M, Liljeström M, Salo J, Santavirta S, Konttinen YT
The Journal of rheumatology 2005 Apr;32(4):713-20

Immunohistochemistry

Supportive validation

Submitted by

R&D Systems (provider)

Main image

Experimental details

TRANCE/TNFSF11/RANK L in Human Lymph Node. TRANCE/TNFSF11/RANK L was detected in immersion fixed paraffin-embedded sections of human lymph node using 5 µg/mL Mouse Anti-Human TRANCE/TNFSF11/RANK L Monoclonal Antibody (Catalog # MAB626) overnight at 4 °C. Tissue was stained with the Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS002) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Blocking/Neutralizing

Supportive validation

Submitted by

R&D Systems (provider)

Main image

Experimental details

Osteoclast-Like Cell Formation Induced by TRANCE/TNFSF11/RANK L and Neutralization by Human TRANCE/TNFSF11/RANK L Antibody. In the presence of Recombinant Mouse M-CSF (20 ng/mL, Catalog # 416-ML), Recombinant Human TRANCE/TNFSF11/RANK L (Catalog # 390-TN) induces osteoclast-like cell formation in RAW 264.7 mouse macrophages in a dose-dependent manner (orange line), as measured by TRAP (tartrate-resistant acid phosphatase) activity in cell lysates. Under these conditions, osteoclast-like cell formation elicited by Recombinant Human TRANCE/ TNFSF11/RANK L (30 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human TRANCE/TNFSF11/RANK L Monoclonal Antibody (Catalog # MAB626). The ND₅₀ is typically 0.8-2.5 µg/mL.